Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2018
SIETES contiene 92571 citas

 
 
<< anterior 21 a 40 de 7951 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original Cita con resumen
22.Enlace a cita original Cita con resumen
Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]
23.Enlace a cita original Cita con resumen
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]
24.Enlace a cita original Cita con resumen
25.Enlace a cita original Cita con resumen
Pylypchuk R, Wells S, Kerr A, Poppe K, Riddell T, Harwood M, Exeter D, Mehta S, Grey C, Wu BP, Metcalf P, Warren J, Harrison J, Marshall R, Jackson R. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391:12 de mayo. [Ref.ID 102612]
26.Enlace a cita original Cita con resumen
Hart RG, Sharma M, Mundl H, Kasner SE, Bagdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonskowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS Investigators. Ribaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-201. [Ref.ID 102610]
27.Enlace a cita original Cita con resumen
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]
28.Enlace a cita original Cita con resumen
Webster P. Pimavanserin evaluated by the FDA. Lancet 2018;391:5 de mayo. [Ref.ID 102594]
29.Enlace a cita original Cita con resumen
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]
30. Cita con resumen
Anónimo. Sclérose en plaques. Prescrire 2018;38:212-3. [Ref.ID 102590]
31. Cita con resumen
Anónimo. Fluoroquinolones: syndrome du canal carpien?. Prescrire 2018;38:110. [Ref.ID 102583]
32.Enlace a cita original Cita con resumen
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:25 de abril. [Ref.ID 102571]
33.Enlace a cita original Cita con resumen
Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. Anti–tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurology 2018;75:939-46. [Ref.ID 102569]
34.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
35.Enlace a cita original Cita con resumen
Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018;89:741-53. [Ref.ID 102555]
36. Cita con resumen
Anónimo. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. European Medical Agency 2018:7 de marzo. [Ref.ID 102551]
38.Enlace a cita original Cita con resumen
D'Silva M, Hallas J, Pottegård A, Kristiansen NS, Atsma WJ, Franks B, D'Silva M, Varas-Lorenzo C, Perez-Gutthann S, Arana J. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. Eur J Clin Pharmacol 2018;74:febrero. [Ref.ID 102545]
39.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
40. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
Seleccionar todas
 
<< anterior 21 a 40 de 7951 siguiente >>